4/29/2024 [**] Certain identified information has been excluded from this exhibit because it is (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omission. [**] [**] [**] [**] [**] [**] [**] [**] [**]

Modification P00011 makes the following changes to the contract: 1. Reduces the annual not to exceed (NTE) amount for option years 5 through 9, 2. Reduces the minimum annual order quantity from [**] of ACAM2000 in Option Years 5 through 9; 3. Increases the total quantity of [**] from [**] and amends the option period in which [**] is provided; 4. Increases the quantity of [**] for Option Year 5 from [**]; and 5. Revises the Performance Work Statement to add [**] to the requirement at no additional cost to the Government. ALL OTHER TERMS AND CONDITIONS REMAIN THE SAME. Details of changes: Option Year 5, NTE amount reduced from [**] Option Year 6, NTE amount reduced from [**] Option Year 7, NTE amount reduced from [**] Option Year 8, NTE amount reduced from [**] Option Year 9, NTE amount reduced from [**] Table 1: Overall Price Summary, amended as follows (changes made by Modification P00011 are shown in red): Item CLIN X001 – Doses CLIN X002 – Diluent Replacement CLIN X003 – Syringe Replacement CLIN X004 – Re-labeling [**] [**] ACAM Testing Grand Total Contract Year ACAM Doses Extended Price Diluent Vials Extended Price Transfer Syringes Extended Price Target Expired Doses/SNS Expired Doses/SNS 000X Base [**] [**] [**] 100X Option Year 1 [**] [**] [**] [**] 200X Option Year 2 [**] [**] [**] [**] 300X Option Year 3 [**] [**] [**] 400X Option Year 4 [**] [**] [**] [**] [**] [**] [**] [**] 500X Option Year 5 [**] [**] [**] [**] [**] [**] [**] [**] [**] 600X Option Year 6 [**] [**] [**] [**] [**] [**] [**] [**] 700X Option Year 7 [**] [**] [**] [**] [**] [**] [**] [**] [**] 800X Option Year 8 [**] [**] [**] [**] [**] [**] [**] [**] 900X Option Year 9 [**] [**] [**] [**] [**] [**] [**] [**] [**] Overall [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Note: [**] Timing for [**] and ACAM testing will be determined annually, following the exercise of the associated annual procurement (CLIN X001). Table 2: Task 1 – ACAM2000 Vaccine Manufacture and Provision to the SNS, amended as follows (changes made by Modification P00011 are shown in red): 0001 (Base) 1001 (Option) 2001 (Option) 3001 (Option) 4001 (Option) Contract Year 08/15/19-09/30/19 10/01/19-09/30/20 10/01/20-09/30/21 10/01/21-10/30/22 10/31/22-09/30/23 Target Exercise- By Date 8/15/2019 12/1/2019 12/1/2020 12/1/2021 12/1/2022 Delivery Target 12/30/2019 12/30/2020 12/30/2021 12/30/2022 12/30/2023 [**] Doses [**] [**] [**] [**] [**] Extended Price [**] [**] [**] [**] [**] [**]Doses [**] [**] [**] [**] [**] Page 2 of 10

Extended Price** [**] [**] $**] [**] [**] [**] Doses [**] [**] [**] [**] [**] Extended Price [**] [**] [**] [**] [**] [**] Doses [**] [**] [**] [**] [**] Extended Price [**] [**] [**] [**] [**] 5001 (Option) 6001 (Option) 7001 (Option) 8001 (Option) 9001 (Option) Contract Year 10/01/23–09/30/24 10/01/24–09/30/25 10/01/25–09/30/26 10/01/26–09/30/27 10/01/27–09/30/28 Target Exercise-By Date 5/31/2024 5/31/2025 5/31/2026 5/31/2027 5/31/2028 Delivery Target 8/31/2024 8/31/2025 8/31/2026 8/31/2027 8/31/2028 [**]Doses [**] [**] [**] [**] [**] Extended Price [**] [**] [**] [**] [**] Supplies, Services, and Requirements: ACAM2000 doses supplied as part of a [**]. [**] Package Insert and Medication Guide to be supplied as digital PDF and posted on Daily Med. (Electronic Medication Guide/Package Insert is contingent upon FDA approval). The [**] are provided on separate pallets. Each kit supports 100 doses. This is a firm-fixed price line item. The unit price listed next to each quantity is a price per dose. The exercise of each CLIN must be completed prior to any obligation to perform work under that CLIN. The Delivery Target is expected to occur by August 31 within the same contract year. Due to the variability in order quantities, long lead times for certain raw materials, and uncertainties related to manufacturing and release, any expected changes to the delivery target date will be negotiated and mutually agreed upon. For the base year and option years one (1) through four (4), guaranteed shelf life at time of delivery is [**] of the [**] expiry from the date of manufacture of the vaccine. For option years five (5) through nine (9), guaranteed shelf life at time of delivery is [**] of the [**] expiry from the date of manufacture for vaccine. Target Exercise-By Date: To communicate its intentions for the upcoming contract year, and to aid in the contractor’s operational planning, the Government will issue a non-binding letter of intent by November 30 each year during option years six (6) through nine (9). Both parties agree the notice is non-binding as funding allocations may not be finalized at the time the letter of intent is issued. Options may be exercised at any point during the designated ordering periods of each year, subject to the availability of funds. The projected target date to exercise options is May 31st. The order quantity per contract year is [**] doses. For the option years five (5) through nine (9), an order may be placed once per contract year in a quantity of [**] doses. Pricing for the [**] and ACAM testing is [**] for ACAM2000. Testing will be performed annually following the execution of each annual procurement in option years five (5) through nine (9). Statement of Work amended to add Task 5: Wetvax Potency Testing (changes shown in red): Section C – Statement of Work (SOW) Title: Warm based manufacturing and license maintenance for ACAM2000 Vaccine C.1. Background and Need As a direct result of the September 11, 2001 tragedy and the increased perceived threat of bio- terrorist activities against the United States, the Department of Health and Human Services (DHHS) and the Assistant Secretary for Preparedness and Response (ASPR) have a need to maintain a contract with the experienced manufacturer to supply its Food & Drug Administration (FDA) licensed ACAM2000, Smallpox (Vaccinia) Vaccine, Live; the only domestically-produced such vaccine, to maintain its ability to manufacture and deliver the licensed vaccine up to 36M doses annually. C.2. Purpose The purpose of this project is to maintain the ability to manufacture and deliver licensed ACAM2000, Smallpox (Vaccinia) Vaccine, Live. The ACAM2000 vaccine shall be manufactured within the United States (US) in accordance with current Good Manufacturing Practices (cGMP) guidelines and palletized kits of ACAM2000 Vaccine, diluent, bifurcated needles and transfer syringes delivered to the ASPR Page 3 of 10

Strategic National Stockpile (SNS). C.3. Scope of Work The Contractor, as an independent organization and not as an agent of the Government, shall furnish all labor, materials, supplies, facilities, equipment, transportation and travel necessary to manufacture and deliver listed doses of licensed ACAM2000 vaccine, in accordance with C.10. The contractor shall deliver an equivalent quantity of ancillaries [**] for use in the administration of the ACAM2000 vaccine. The contractor shall perform [**] provided by the ASPR/SNS. The contractor shall comply with the following objectives: (Task 1) Manufacture and deliver, Food & Drug Administration (FDA) licensed ACAM2000 under Biologic License Application (BLA) Submission Tracking Number (STN) 125158 from approved facilities with the timeframe and quantities in accordance with Task 1. (Task 1) Maintain the agency-approved Stability testing structure which assesses the long- term safety and efficacy of the ACAM2000 Lyophilized Drug Product at the Strategic National Stockpile and supports [**] of shelf life ([**]) from the time of product manufacture. (Task 1) Perform [**] on ACAM2000. (Task 2) Replace expiring ACAM2000 diluent as related to new doses supplied under this contract (Task 3) Replace expiring transfer syringes as related to new doses supplied under this contract (Task 4) Relabel vaccine to [**] shelf-life (Task 5) Perform [**] provide by ASPR. (C.5.) Provide quarterly reports and update meetings by the 30th day following the end of the quarter. C.4 Task 1: Manufacturing and Delivery of ACAM2000 Vaccine The Contractor shall manufacture and deliver, in accordance with this Task 1, licensed ACAM2000, including ancillary components which shall be delivered to the SNS annually, and produced entirely in the US in accordance with this Statement of Work. The product shall meet all requirements as specified in the approved FDA license and any approved supplements or amendments thereto. Ancillary components include [**] One vial of [**] will be provided for USP for each [**] The vaccine and [**] will be labeled and packaged as outlined in the BLA and subsequently approved FDA license. Manufacture of Bulk Vaccine The contractor shall manufacture the cell cultures required for the domestic production of ACAM2000 at its US bulk vaccine manufacturing facility at the 500L bioreactor scale. The contractor shall perform all Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) on any equipment required to produce the vaccine. The domestic manufacturing of the ACAM2000 vaccine in Vero cells grown on micro carrier beads at the 500 Liter scale shall be in accordance with the approved ACAM2000 BLA on file with the FDA. Vaccine Fill and Finish The Contractor shall maintain a validated filling, lyophilization, labeling and packaging of ACAM2000 at its US fill and finish facility and shall perform all IQ, OQ, and PQ on any additional equipment required at that facility and associated process development. Requirements for Packaging & Delivery The products shall be delivered as follows: ACAM2000, (Smallpox (Vaccinia) Vaccine, Live), shall be provided in a multiple dose [**]. Each vial shall contain [**] after reconstitution with [**]. Each vaccine box shall Page 4 of 10

contain [**]. Each case shall contain [**]. For the base and option years one (1) through four (4), the guaranteed shelf life at time of delivery is [**] of the [**]expiry date from the date of manufacture of the vaccine. For option years five (5) through nine (5), the guaranteed shelf life at time of delivery is [**] of the [**] expiry from the date of manufacture for the vaccine. ACAM2000 Diluent shall be provided as [**] Each diluent box shall contain 50 vials. Each case shall contain [**]. The diluent shall have a [**] shelf life. The diluent should have [**] of shelf life remaining at the time of delivery. Bifurcated needles shall be supplied in boxes containing [**] each. Each case shall contain [**] bifurcated needles with an expiry date of [**] from date of manufacture. Transfer Syringes shall be provided as [**]. Each box shall contain [**] per case. Transfer syringes have an expiry date of [**] from the date of manufacture. [**] Complete, unopened cases of [**] will be provided. The additional quantity required to provide complete cases (rounded up quantity in excess of [**] requirements) will be provided at no additional cost to the Government). The provided kit summary should note both the Emergent lot number and the manufacturer’s lot number for needles and syringes. FDA-approved ACAM2000 Package Insert and Medication Guides shall be provided per the license as a compact disk (CD). Emergent will work with the FDA to phase-out the CDs and provide a suitable electronic solution. The contractor shall notify the Contracting Officer’s Representative (COR) when the Package Insert or Medication Guide are revised and will ship the current PDF version with each delivery order. Boxes, cases and shelf cartons shall not contain mixed lot numbers. All pallets are to have the identical TiHi stack pattern except for the last final pallet per lot number. All ACAM2000 vaccine product shall be delivered on standard 48" by 40" pallet, not to exceed 60” in height, stretch wrapped and secured to pallet for safe transport. Prior to an ACAM2000 vaccine and ancillary delivery, the Kit Component Inventory Summary Sheet which provides the ACAM2000 Kit [**] Inventory Summary, shall be provided outlining the products in each delivery; lot numbers of each item; number of full and partial boxes, cases and pallets; and the total quantities of each items in vials or each. The contractor shall provide Certificates of Analysis and Certificates of Conformance for the vaccine at least 3 days prior to shipment arriving at the SNS facility. The contractor shall also provide Certificates of Analysis and Vendor Certificate of Manufacturing (or Conformance) for the diluent prior to shipment arriving at the SNS facility. Driver information for each delivery truck shall be provided as soon as available to the SNS site. After the delivery, a documented review of the temperature data from the vaccine and diluent shipments will be provided. SNS Locations Delivery location shall be in accordance with United States Government (USG) instructions provided one (1) month prior to the shipment and are specific exclusively to Continental US (CONUS) locations. Locations outside CONUS may incur additional shipping/validation charges which will result in a contract modification to be performed prior to shipment. No more than[**] annually. Vaccine relabeling shall occur at current inventory locations unless otherwise agreed upon. Delivery shall also include ancillary items for reconstitution of each vial of vaccine (diluent, transfer syringe) as well as a bifurcated needle for administration of each dose of vaccine. Packaging, labeling and delivery shall be done according to the methodology and specifications outlined in the current BLA filed with the FDA and as outlined in Section C.6, C.8. Section D, Section E. Page 5 of 10

Warranties A warranty shall be provided for vaccines, diluent, transfer syringes, and bifurcated needles delivered to the USG during this 10-year contract. Vaccine will have [**] of shelf-life remaining at time of delivery for the base and option years one (1) through four (4). Vaccine will have [**] of shelf-life remaining at time of delivery for option years five (5) through nine (9). Diluent will have [**] of shelf-life remaining at time of delivery. The transfer syringes should have [ **] of shelf life remaining at the time of delivery. Transfer Syringes and Needles are commercial products. In the event of supplier and/or delivery issues that result in shelf life not meeting minimum requirements, the parties will develop suitable alternatives in delivery and pricing. For ACAM2000 delivered during this contract, if it is determined that the ACAM2000 vials delivered do not meet the shelf life standard of [**] expiry from the date of manufacture (with a minimum of [**] of shelf life remaining at the time of delivery) and that USG has met its storage and handling obligations for such products pursuant to a separate Quality Agreement, then the Contractor will provide an equitable remedy based on the remaining shelf life of the non-conforming product(s), which will include one of the following: (a) replacement product (only during the contract period), (b) a credit against future purchases under the contract, or (c) reimbursement. Historical Lots- Testing Program and Quarantine Doses manufactured and distributed prior to 2018 had labeled expiry periods of less than the current 16- year expiry. As these lots approach their labeled expiry dates, Emergent will coordinate with SNS and the SNS sites to re-label impacted lots with [**]. Once lots have exceeded the FDA approved [**] expiry, they will be quarantined by SNS and will not be distributed for any use. Given the commitment for a long-term contract to replace the stockpile, Emergent will agree to test representative lots of quarantined product on an annual basis and provide the data as For Information Only (FIO) to SNS until replenished stockpile inventory levels meet the desired threat assessment level. This information will be provided as soon as it is available and following the Government placing its annual optional CLIN order for at least 9 million ACAM2000 doses. Under this Vaccine Testing Program, Emergent understands that, in the event of an emergency, the SNS would be responsible for seeking an appropriate regulatory mechanism to deploy for use quarantined product. The contractor is permitted to follow its own procedures for stability testing of historical lots. In the event of an unexpected or atypical result, the contractor may conduct an investigation to rule out laboratory error. Upon confirmation of the results and testing, results shall be shared with the SNS; Up to seven (7) historical lots shall be tested; Testing would continue only with the concurrent exercise of the option for product delivery; Testing would only continue until the stockpile reaches the threat assessment level ([**] doses); Based on the lots tested and the proposed delivery schedule, the maximum that lots would be tested is anticipated to be no more than [**] from the date of manufacture; The product expiration will remain at [**]. This testing will not be used to support any further extension to the product expiry dating. Under this agreement, the product maintained in the SNS stockpile beyond the shelf life of [**] is no longer considered to be under our license. Emergent is not making any representation or guarantees that the testing will support extensions to the shelf life and the testing data is not being provided to the SNS in support of expiry extensions. As a result, Emergent will also no longer be performing any activities beyond the submission of the data to the SNS. The testing data is not being provided to the SNS in support of expiry extensions, and any discussions with the FDA regarding the use of the stockpile in an emergency event or any use of this product will be captured under a different regulatory mechanism outside of Emergent’ s license and will be the responsibility of the SNS. Page 6 of 10

The following table provides a summary detailing the strategy for managing expiring ACAM2000 vaccine: Table 6: Strategy for managing expiring ACAM2000 vaccine Task 2: Diluent Replacement The contractor shall replace expiring ACAM2000 diluent related this contract (see Task 2 table). Government to provide forecast annually to confirm the quantity to be delivered Options may be exercised after the base year is awarded through year 10 at the quantities also outlined herein. If the quantity of diluent requiring replacement changes from the quantity outlined in Section C.6, both parties shall agree to the change. Note timing listed in C.6 are approximations as replacement timing is dependent of the manufacturing date of shipped quantities. The contractor shall deliver [**]. The diluent shall be packaged in [**] vials per case. The diluent shall have a [**] shelf life. At the time of delivery to the SNS the diluent should have [**] of shelf life remaining. Task 3: Syringe Replacement Transfer Syringe quantities will be in increments of a full case box (divisible by [**]). Replacement of transfer syringes sold prior to this contract are outside the scope of this proposal and can be quoted separately upon request. Task 4: ACAM2000 Vaccine Limited Re-Labeling Activities The ACAM2000 vaccine currently has an expiration date of [**] Emergent will re-label vaccine lots located at the Strategic National Stockpile (SNS) for lots produced by the Rockville MD facility which have less than an expiry of [**] as they approach their current labeled expiration. (See table below). Quantities are estimates and will be verified prior to relabeling efforts. Task 5: [**] Category Proposed Strategy Older lots with [**] since date of manufacture All lots can be managed as having [**] per STN 125158/203 (approved 15 Dec 2017). These lots will be re- labeled with [**] expiry per the schedule in Section C below. Once these lots exceed [**] the lots will be quarantined by SNS, per below. Older lots that have [**] since date of manufacture These lots have, or will have, exceeded the FDA approved expiry period and will be quarantined by SNS. The lots will not be distributed by ASPR for any purpose (vaccination, research, etc.) except under an approved appropriate regulatory mechanism. Once SNS has achieved its inventory goal for ACAM2000 vaccine, all quarantined expired doses should be destroyed. New lots with [**] expiry* *It is expected the U.S. Government will deploy in date vaccine first and quarantined vaccine would only be deployed after all in date product is depleted (and with the appropriate regulatory oversight). All newly manufactured lots under this contract will be labeled with [**] expiry. Therefore, none of these lots will expire during the [**] period of this contract. When the lots do expire in the future, the expired materials should be destroyed. Page 7 of 10

[**] Table 7: Re-labeling of Rockville MD Manufactured Lots with [**] expiry Page 8 of 10 [**]

C.5. Reporting Requirements (Emergent) The contractor shall submit a Quarterly Progress Report, which shall include the information listed below that is applicable for the performance period during the quarter being reported. The contractor shall provide the Contracting Officer’s Representative (COR) with one electronic copy of the Quarterly Progress Report via e-mail. Any attachments to the report shall be submitted in Microsoft Word, Adobe Acrobat, or similar files. The contractor shall meet with the COR quarterly to discuss the Quarterly Progress Report. The contractor shall submit the Quarterly Reports and schedule the meetings by the 30th day following the end of the quarter. The following shall be included in the quarterly report. 1. Quarterly Reporting Requirements Manufacturing and Delivery of ACAM2000® Kits a. Procurement and Production b. Quality Control Testing and Potency c. Quality Manufacturing Deviations (major) 2. FDA inspections, consultation results or recommendations and any files to the FDA concerning the ACAM2000 BLA 3. Security Assessment 4. Stability Program Assessment (Provided Annually) 5. Overall Project Assessment a. Delivery Summary b. Projected Deliveries for next reporting period c. Plan vs. Actual and Specific problems to address C.6. Reporting Requirements (SNS) SNS shall provide the following information to Emergent at the frequency described below: 1. Doses delivered from SNS. This number is needed for safety reporting (ANNUALLY, October) 2. Destruction of expired lots of ACAM Vaccine. (ANNUALLY for record retention) 3. ACAM Vaccine lots in inventory, number of vials, and quantity in quarantine. (ANNUALLY for over-labelling planning) 4. ACAM Diluent lots in inventory, number of vials. (ANNUALLY) 5. Note: Updated inventory on specific lots may be required as part of investigations throughout the contract. 6. The Contractor shall prepare and submit the following report: Report Type Description Format Due Date Monthly Status Report The contractor shall report on contractor’s compliance with the requirements of FAR 52.223-99 Ensuring Adequate COVID-19 Safety Protocols for Federal Contractors (OCT 2021) (Deviation) Email to the Contracting Officer and COR Monthly, no later than the 5th calendar day of the month following the previous monthly period of performance. C.7. Delivery Notifications Emergent shall notify the COR of the total quantity of product(s) and pallet count that will be delivered utilizing the Kit Component Inventory Summary Sheet, which provides the ACAM2000 Kit [**] Inventory Summary to the SNS at least five (5) business days prior to each delivery. C.8. Quality Inspections Site Visits/Audits: The Government shall perform annual site visits/security audits as deemed necessary by the Government throughout the period of performance of the contract. Quality: The Government reserves the right to visit the contractor’s site for purposes of Page 9 of 10

assessing quality on an annual basis or as deemed necessary by the Government throughout the period of performance of the contract. Notice: The Government will provide 2 weeks advance notice prior to the Contractor of all site visits and audits. The notice will include a statement concerning the intended scope of the audit and a list of the required documents or access to personnel. Note: Facilities with live vaccine is in use (core production/testing areas) require vaccinations or waivers prior to entry. All audits will be conducted between normal business hours i.e., 8 a.m. through 4 p.m., Monday through Friday. Report to be provided by the Government as to any observations associated with site visits/audits. The government reserves the right to inspect any contractor or subcontractor facility used for the manufacture, packaging, storage, transportation or any other handling of products ordered as a result of this contract without prior notice. These inspections do not replace any required inspections conducted by the FDA but are in addition to such inspections. The contractor will be required to respond to any finding’s resultant from these inspections with remediation plans or an explanation of why no remediation is required. Page 10 of 10

Q1 2024 Financial Results Update May 1, 2024 1

PROPRIETARY AND CONFIDENTIAL 2 Q1 2024 Update Introduction

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement contained herein. Any such forward-looking statement speaks only as of the date of this presentation, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasure ("MCM") products, including CYFENDUS® (Anthrax Vaccine Adsorbed (AVA), Adjuvanted), BioThrax® (Anthrax Vaccine Adsorbed) and ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), among others, as well as contracts related to development of medical countermeasures; the availability of government funding for our other commercialized products, including EbangaTM (ansuvimab-zykl), BAT® (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)) and RSDL® (Reactive Skin Decontamination Lotion Kit); our ability to meet our commitments to quality and compliance in all of our manufacturing operations; our ability to negotiate additional USG procurement or follow-on contracts for our MCM products that have expired or will be expiring; the commercial availability and acceptance of over-the-counter NARCAN® (naloxone HCl) Nasal Spray; the impact of the generic marketplace on NARCAN® (naloxone HCI) Nasal Spray and future NARCAN® sales; our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries; our ability to provide Bioservices for the development and/or manufacture of product and/or product candidates of our customers at required levels and on required timelines; the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations; our ability to negotiate further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing under our existing Bioservices contracts; our ability to collect reimbursement for raw materials and payment of services fees from our Bioservices customers; the results of pending stockholder litigation and government investigations and their potential impact on our business; our ability to comply with the operating and financial covenants required by our senior secured credit facilities and the amended and restated credit agreement relating to such facilities, as amended from time to time, as well as our 3.875% Senior Unsecured Notes due 2028; our ability to maintain adequate internal control over financial reporting and to prepare accurate financial statements in a timely manner; our ability to resolve the going concern qualification in our consolidated financial statements and otherwise successfully manage our liquidity in order to continue as a going concern; the procurement of our product candidates by USG entities under regulatory authorities that permit government procurement of certain medical products prior to FDA marketing authorization, and corresponding procurement by government entities outside of the United States; our ability to realize the expected benefits of the sale of our travel health business to Bavarian Nordic; the impact of the organizational changes we announced in January 2023 and August 2023; our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria; the impact of cyber security incidents, including the risks from the unauthorized access, interruption, failure or compromise of our information systems or those of our business partners, collaborators or other third parties; the success of our commercialization, marketing and manufacturing capabilities and strategy; and the accuracy of our estimates regarding future revenues, expenses, capital requirements and needs for additional financing. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Readers should consider this cautionary statement, as well as the risks identified in our periodic reports filed with the Securities and Exchange Commission, when evaluating our forward-looking statements. Trademarks Emergent®, BioThrax®, RSDL®, BAT®, Anthrasil®, CNJ-016®, ACAM2000®, NARCAN®, CYFENDUS®, TEMBEXA® and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners. 3 Safe Harbor Statement/Trademarks INTRODUCTION

Agenda 4 Q1 2024 Update INTRODUCTION Presenter Topic(s) Joseph C. Papa President and CEO • Transformation Plan Update Rich Lindahl EVP, CFO and Treasurer • Q1 2024 Financial Review • FY 2024 and Q2 2024 Guidance Joseph C. Papa President and CEO • Driving Profitable, Sustainable Long-Term Growth • Closing Remarks Q&A

PROPRIETARY AND CONFIDENTIAL Q1 2024 Update Transformation Plan Update Joseph C. Papa President and Chief Executive Officer 55

Transformation Plan Update 6 Transformation Plan Update Multi-year plan to stabilize, turnaround and transform. • Our mission is unchanged Q1 stabilization efforts and priorities: Continued focus on MCM and NARCAN® Nasal Spray as core business drivers • Strengthened engagement with U.S. government customer stakeholders • Clarity gained on anthrax procurement levels • New MCM contract awards and orders from the USG & DOD throughout 2024 ◦ VIGIV, BAT and ACAM2000 • Solid performance across public interest and retail channels for NARCAN® Nasal Spray Sharpened strategy on future growth drivers • Created and added new Chief Science Officer role, reporting to CEO • Refreshed LCM initiatives over 2+ years • 2024 catalysts and future drivers meets customer and patient needs Leading with integrity through a culture of quality and compliance across our enterprise. Addressed debt repayment; improved operating performance and profitability • Significant restructuring efforts • Reorganization expected to yield annualized savings of ~$80 million • Reduction in workforce (~300 filled roles) • New bank amendment executed on April 29 provides incremental runway to execute go-forward plan • Initiated efforts to divest certain products/ sites; already received multiple offers on one of our smaller sites

Rich Lindahl Executive Vice President and Chief Financial Officer Q1 2024 Update Financials

Key Financial Performance Metrics Q1 2024 vs. Q1 20231 8 Total Revenues Adjusted EBITDA2 Adjusted Net Income (Loss)2 FINANCIALS ($ in millions) Q1 2023 Q1 2024 1. All financial information incorporated within this presentation is unaudited. 2. See "End Notes: Non-GAAP Financial Measures" and "Appendix" for the definitions of non-GAAP terms and reconciliations to the most directly comparable GAAP financial measures. $300.4 $164.3 Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024 $66.9 $(101.5) $31.1 $(163.5) $148.0 $7.2 5%51% Total Segment Adjusted Gross Margin2 --- Total Segment Adjusted Gross Margin %2

Notable Revenue Elements Q1 2024 vs. Q1 20231 9 FINANCIALS 1.All financial information incorporated within this presentation is unaudited. 2. Product sales, net are reported net of variable consideration including returns, rebates, wholesaler fees and prompt pay discounts in accordance with U.S. generally accepted accounting principles. ($ in millions) Q1 2024 Q1 2023 % Change Product sales, net (2): NARCAN® $ 118.5 $ 100.4 18 % Other Commercial Products — 5.8 (100) % Anthrax MCM 55.9 21.9 155 % Smallpox MCM 50.2 7.2 * Other Products 49.3 8.1 * Total Product sales, net $ 273.9 $ 143.4 91 % Bioservices: Services $ 18.3 $ 12.6 45 % Leases 0.2 1.8 (89) % Total Bioservices revenues $ 18.5 $ 14.4 28 % Contracts and grants $ 8.0 $ 6.5 23 % Total revenues $ 300.4 $ 164.3 83 % * % change is greater than +/- 200%

Key Financial Performance Metrics Q1 2024 vs. Q1 2023 1 10 SG&A $ --- SG&A Margin %2 FINANCIALS ($ in millions) 1.All financial information incorporated within this presentation is unaudited. 2. SG&A Margin is calculated as Gross SG&A Expense divided by total revenues. Q1 2023 Q1 2023 Q1 2023 Q1 2023 Q1 2023 Q1 2024 Q1 2024 Q1 2024 Q1 2024 Q1 2024 $15.1 $40.7 $84.7 $101.3 62%28% Cost of Commercial Product Sales Cost of MCM Product Sales Cost of Bioservices R&D $ Q1 2024 Q1 2023 $52.1 $45.8 $62.2 $55.4 $30.3 $51.7

Segment Reporting Q1 2024 vs. Q1 20231 11 Revenue Segment Adjusted Gross Margin 2 --- Segment Adjusted Gross Margin % 2 Segment Adjusted Gross Margin 2 --- Segment Adjusted Gross Margin % 2 Revenue FINANCIALS ($ in millions) COMMERCIAL PRODUCTS SEGMENT MCM PRODUCTS SEGMENT 1.All financial information incorporated within this presentation is unaudited. 2. See "End Notes: Non-GAAP Financial Measures" and "Appendix" for the definitions of non-GAAP terms and reconciliations to the most directly comparable GAAP financial measures. Q1 2023 Q1 2024 $118.5 $106.2 Q1 2023 $66.4 $60.4 Q1 2023 Q1 2023 Q1 2023 Q1 2024 Q1 2024 Q1 2024 $155.4 $37.2 Q1 2024 57%56% (43)% Segment Adjusted Gross Margin 2 --- Segment Adjusted Gross Margin % 2 Revenue SERVICES SEGMENT $18.5 $14.4 Q1 2023 Q1 2023 Q1 2024 Q1 2024 $(37.3)$(12.0) (259)%(65)% $93.6 $(15.9) 60%

Balance Sheet & Cash Flow Metrics 12 FINANCIALS As of March 31, 2024 For the Three Months Ended March 31, 2024 CASH $78.5 ACCOUNTS RECEIVABLE, NET $233.5 TOTAL DEBT $909.2 NET DEBT1,2, 3 $830.7 OPERATING CASH FLOW $(62.6) CAPITAL EXPENDITURES $10.8 ($ in millions) 1.Debt amount indicated on the Company’s balance sheet is net of unamortized debt issuance costs of $3.3M. 2.Net Debt is calculated as Total Debt minus Cash and cash equivalents ($909.2M - $78.5M = $830.7). 3. See "End Notes: Non-GAAP Financial Measures" and "Appendix" for the definitions of non-GAAP terms and reconciliations to the most directly comparable GAAP financial measures.

2024 Forecast – Updated as of 05/01/2024 13 FINANCIALS 1. See "End Notes: Non-GAAP Financial Measures" and "Appendix" for the definitions of non-GAAP terms and reconciliations to the most directly comparable GAAP financial measures. 2.Other Commercial products, which includes Vivotif® and Vaxchora®, which were sold to Bavarian Nordic as part of our travel health business in May 2023, are not included in the 2024 forecast. METRIC ($ in millions) Updated Range (as of 05/01/2024) Action Previous Range (as of 03/06/2024) Total revenues $1,000 - $1,100 REVISED $900 - $1,100 Net loss $(148) - $(98) REVISED $(183) - $(133) Adjusted net loss (1) $(65) - $(15) REVISED $(130) - $(80) Adjusted EBITDA (1) $125 - $175 REVISED $50 - $100 Total segment adjusted gross margin % (1) 44% - 47% REVISED 40% - 45% Segment Level Revenue (2) Commercial Products $460 - $500 UNCHANGED $460 - $500 MCM Products $440 - $490 REVISED $340 - $490 Services $70 - $80 UNCHANGED $70 - $80 METRIC ($ in millions) Q2 2024 Forecast Total revenues $160 - $210 Key Assumptions ($ and shares in millions) Updated Range (as of 05/01/2024) Interest expense ~$82 R&D ~6% of Revenue Weighted avg. fully diluted share count ~52 Capex ~$32 Depreciation & amortization ~$111

Driving Profitable, Sustainable Long- Term Growth

PROPRIETARY AND CONFIDENTIAL New Survey Findings Underscore Importance of Naloxone Access (n=1,005 survey )1 Approximately 90% of respondents/adults (18+) includes parents across the U.S. who agree: • The number of opioid deaths is unacceptable; and they would help save someone from an opioid overdose, given the opportunity • It’s important for NARCAN® Nasal Spray to be available and accessible to buy OTC without the need for a prescription • Opioid overdose is a concern for teenagers and college students • Schools, public libraries, dorms, and professionals who work with teenagers and college kids should have access to NARCAN® Nasal Spray 1515 NARCAN® Nasal Spray Q1 Highlights • Continued to meet demand through public interest distribution and widespread availability across major retailers and e-commerce sites • Pursuing additional channels to expand access, e.g. businesses, workplaces ◦ Launched NarcanWorkplace.com ◦ Partnered with National Safety Council on workplace outreach (contracted commercial partner • Engaged Emerson Group to help expand the reach of OTC retail program • Committed to White House Challenge to Save Lives from Overdose 1. Data on file. Online Survey conducted by Bryter Global on behalf of Emergent BioSolutions; April 24 through April 28, 2024. Widespread Support for Expanded Access to NARCAN® Nasal Spray

PROPRIETARY AND CONFIDENTIAL • Opioid settlement $54+B flowing into states over next 10-15 years • Demand for naloxone is expected to increase as the epidemic continues and federal/state programs continue to combat the crisis • Greater policy focus to stock naloxone in schools, as seen in many states, e.g. Colorado and Michigan • In terms of programs that facilitate access to naloxone, the following figures were allocated: ◦ Substance Use Prevention, Treatment, and Recovery Services Block Grant (SUBG): $1.928B ◦ State Opioid Response Grants: $1.575B • Ongoing opportunities in Canada • Product kits and line extensions • Exploring international markets, OTC partnering opportunities 2024 & Beyond -- Catalysts / Future Drivers for NARCAN® Nasal Spray 16

PROPRIETARY AND CONFIDENTIAL NARCAN® Nasal Spray Update Paul Williams SVP, Head of Products Business 17 Key MCM Business Highlights • Increasingly dangerous world / ongoing focus on CBRN threats remains vital ◦ Recent events across the EU have ignited greater preparedness efforts ◦ Mpox estimates up to 31 cases per month since 20231 ◦ Recently published 'Box the Pox' report by The Bipartisan Commission on Biodefense outlines preparedness plan and recommendations •New MCM contract awards and orders from the U.S. Government & DOD throughout 2024 ◦ Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) ◦ Greater clarity on 2024 CYFENDUS procurement levels ◦ VIGIV, BAT and ACAM2000 (notices of intent to procure) 17 1. CDC MMWR Report: https://www.cdc.gov/mmwr/volumes/72/wr/mm7220a2.htm

PROPRIETARY AND CONFIDENTIAL NARCAN® Nasal Spray Update Paul Williams SVP, Head of Products Business 18 2024 & Beyond -- Catalysts / Future Drivers for MCM Business •Continued high-risk threats; Final FY 2024 Congressional Funding Figures for key programs ◦ On the biodefense front, these programs received the following appropriations: ▪ Biomedical Advanced Research and Development Authority (BARDA): $1.015B ▪ Strategic National Stockpile (SNS): $980M ▪ Project BioShield Special Reserve Fund (SRF) $825M • International government opportunities ◦ Focus on EU-level stockpiling approach for MCMs to be used in health emergencies ◦ HERA engagement and collaboration •Anticipated ACAM2000 Mpox FDA approval for second half of 2024 18

Product Portfolio | Future Growth Drivers 19PROPRIETARY AND CONFIDENTIAL

Summary 20 FINANCIALS • First quarter results reflect mix of strong performance in certain core areas offset by ongoing challenges • New contract awards and orders from the U.S. Government & DOD throughout 2024 • Notable progress on strengthening our business fundamentals • Positioned for success, driven by our unique focus on protecting communities and addressing global health threats • Near-term priority is to focus on stabilizing the business • Strong performance for NARCAN® Nasal Spray; continuing to broaden access is critical to help save lives

PROPRIETARY AND CONFIDENTIAL 21 Q&A

In this presentation, we sometimes use information derived from consolidated and segment financial information that may not be presented in our financial statements or prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). Certain of these financial measures are considered not in conformity with GAAP (“non-GAAP financial measures”) under the United States Securities and Exchange Commission (“SEC”) rules. Specifically, we have referred to the following non-GAAP financial measures: • Adjusted Net Income (Loss) • Adjusted EBITDA • Total Segment Revenues • Total Segment Gross Margin • Total Segment Gross Margin % • Total Segment Adjusted Gross Margin • Total Segment Adjusted Gross Margin % • Segment Adjusted Gross Margin • Segment Adjusted Gross Margin % • Net Debt We define Adjusted Net Income (Loss) which is a non-GAAP financial measure, as net income (loss) excluding the impact of changes in fair value of contingent consideration, acquisition and divestiture-related costs, severance and restructuring costs, other income (expense) items, and non-cash amortization charges. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results and GAAP financial measures, provide management and investors with an additional understanding of our business operating results, including underlying trends. We define Adjusted EBITDA, which is a non-GAAP financial measure, as consolidated net income (loss) before income tax provision (benefit), interest expense, net, depreciation, amortization of intangible assets, changes in fair value of contingent consideration, severance and restructuring costs, other income (expense) items and acquisition and divestiture-related costs. We believe that this non-GAAP financial measure, when considered together with our GAAP financial results and GAAP financial measures, provides management and investors with a more complete understanding of our operating results, including underlying trends. In addition, EBITDA is a common alternative measure of operating performance used by many of our competitors. It is used by investors, financial analysts, rating agencies and others to value and compare the financial performance of companies in our industry, although it may be defined differently by different companies. Therefore, we also believe that this non-GAAP financial measure, considered along with corresponding GAAP financial measures, provides management and investors with additional information for comparison of our operating results with the operating results of other companies. We have included the definitions of Segment Gross Margin and Segment Gross Margin %, which are GAAP financial measures, below in order to more fully define the components of certain non-GAAP financial measures presented in this presentation. We define Segment Gross Margin, as a segment's revenues, less a segment's cost of sales or services. We define Segment Gross Margin %, as Segment Gross Margin as a percentage of a segments revenues. We define Segment Adjusted Gross Margin, which is a non-GAAP financial measure as Segment Gross Margin excluding the impact of restructuring costs and non-cash items related to changes in the fair value of contingent consideration. We define Segment Adjusted Gross Margin %, which is a non-GAAP financial measure, as Segment Adjusted Gross Margin as a percentage of a segment's revenues. We define Total Segment Revenues, which is a non-GAAP financial measure, as our total revenues, less contracts and grants revenue, which is also equal to the sum of the revenues of our reportable operating segments. We define Total Segment Gross Margin, which is a non-GAAP financial measure, as Total Segment Revenues less our aggregate cost of sales or services. We define Total Segment Gross Margin %, which is a non-GAAP financial measure, as Total Segment Gross Margin as a percentage of Total Segment Revenues. We define Total Segment Adjusted Gross Margin, which is a non-GAAP financial measure, as Total Segment Gross Margin, excluding the impact of restructuring costs and changes in the fair value of contingent consideration. We define Total Segment Adjusted Gross Margin %, which is a non-GAAP financial measure, as Total Segment Adjusted Gross Margin as a percentage of Total Segment Revenues. We define Net Debt, which is a non-GAAP financial measure, as our total debt less our cash and cash equivalents. We believe this non-GAAP financial measure, when considered together with our GAAP financial results, provides management and investors with an additional understanding of the Company's ability to pay its debts. Non-GAAP financial measures are not defined in the same manner by all companies and may not be comparable with other similarly titled measures of other companies. The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. For additional information on the non- GAAP financial measures noted here, please refer to the reconciliation tables provide in the Appendix to this presentation as well as the associated press release which can be found on the Company’s website at www.emergentbiosolutions.com. 22 End Notes: Non-GAAP Financial Measures

Streamlining the Emergent Network Update

Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) 25 APPENDIX (unaudited, $ in millions) Three Months Ended March 31, 2024 2023 Source Net income (loss) $ 9.0 $ (186.2) Adjustments: Non-cash amortization charges $ 23.2 $ 18.0 Intangible Asset ("IA") Amortization, Other Income Changes in fair value of contingent consideration 0.5 0.3 MCM Product COGS Severance and restructuring costs (0.5) 9.7 COGS, SG&A and R&D Acquisition and divestiture costs — 1.1 SG&A Other income (expense), net items 3.1 — Other Income (Expense) Tax effect (4.2) (6.4) Total adjustments: $ 22.1 $ 22.7 Adjusted net income (loss) $ 31.1 $ (163.5)

Reconciliation of Net Income (Loss) to Adjusted EBITDA 26 APPENDIX (unaudited, $ in millions) Three Months Ended March 31, 2024 2023 Net income (loss) $ 9.0 $ (186.2) Adjustments: Depreciation & amortization $ 27.9 $ 34.6 Income taxes 3.1 25.6 Total interest expense, net 23.8 13.4 Changes in fair value of contingent consideration 0.5 0.3 Severance and restructuring costs (0.5) 9.7 Acquisition and divestiture costs — 1.1 Other income (expense), net items 3.1 — Total adjustments $ 57.9 $ 84.7 Adjusted EBITDA $ 66.9 $ (101.5)

Reconciliations of Total Revenues to Total Segment Revenues and of Segment and Total Segment Gross Margin and Gross Margin % to Segment and Total Segment Adjusted Gross Margin and Adjusted Gross Margin % 27 APPENDIX Three Months Ended March 31, 2024 (unaudited, in millions) Commercial Products MCM Products Services Total Segment Contracts & Grants Total Revenues Revenues $ 118.5 $ 155.4 $ 18.5 $ 292.4 $ 8.0 $ 300.4 Cost of sales or services 52.1 62.2 30.3 144.6 Gross margin $ 66.4 $ 93.2 $ (11.8) $ 147.8 Gross margin % 56 % 60 % (64) % 51 % Add back: Changes in fair value of contingent consideration $ — $ 0.5 $ — $ 0.5 Restructuring costs — (0.1) (0.2) (0.3) Adjusted gross margin $ 66.4 $ 93.6 $ (12.0) $ 148.0 Adjusted gross margin % 56 % 60 % (65) % 51 % Three Months Ended March 31, 2023 (unaudited, in millions) Commercial Products MCM Products Services Total Segment Contracts & Grants Total Revenues Revenues $ 106.2 $ 37.2 $ 14.4 $ 157.8 $ 6.5 $ 164.3 Cost of sales or services 45.8 55.4 51.7 152.9 Gross margin $ 60.4 $ (18.2) $ (37.3) $ 4.9 Gross margin % 57 % (49) % (259) % 3 % Add back: Changes in fair value of contingent consideration $ — $ 0.3 $ — $ 0.3 Restructuring costs — 2.0 — 2.0 Adjusted gross margin $ 60.4 $ (15.9) $ (37.3) $ 7.2 Adjusted gross margin % 57 % (43) % (259) % 5 %

Reconciliation of Total Debt to Net Debt 28 APPENDIX (unaudited, $ in millions) As of March 31, 2024 Total Debt $ 909.2 Less: Cash and cash equivalents $78.5 Net debt $ 830.7

Reconciliation of Net Loss to Adjusted Net Loss – FY 2024 Forecast 29 APPENDIX ($ in millions) 2024 Full Year Forecast Source Net loss $(148) - $(98) Adjustments: Non-cash amortization charges $65 IA Amortization Other Income Changes in fair value of contingent consideration 2 MCM Product COGS Severance and restructuring costs 21 COGS, SG&A and R&D All Other 5 Acquisition/divestiture costs and non operating investment loss Tax effect (10) Total adjustments: $83 Adjusted net loss $(65) - $(15)

Reconciliation of Net Loss to Adjusted EBITDA – FY 2024 Forecast 30 APPENDIX ($ in millions) 2024 Full Year Forecast Net loss $(148) - $(98) Adjustments: Depreciation & amortization $111 Income taxes 52 Total interest expense, net 82 Changes in fair value of contingent consideration 2 Severance and restructuring costs 21 All other 5 Total adjustments $273 Adjusted EBITDA $125 - $175

Reconciliations of Forecasted Total Revenues to Forecasted Total Segment Revenues and of Forecasted Segment and Total Segment Gross Margin and Gross Margin % to Forecasted Segment and Total Segment Adjusted Gross Margin and Adjusted Gross Margin % 31 APPENDIX (in millions) 2024 Full Year Forecast Total revenues $1,000 - $1,100 Contracts & Grants (30) Total segment revenues $970 - $1070 Cost of sales or services $551 - $575 Total segment gross margin $419 - $495 Total segment gross margin % 43% - 46% Add back: Changes in fair value of contingent consideration $2 Severance and restructuring costs $5 Total segment adjusted gross margin $426 - $502 Total segment adjusted gross margin % 44% - 47%